Pliant Therapeutics' Bexotegrast Meets Primary, Secondary Endpoints in Phase 2a Liver Fibrosis Trial
Portfolio Pulse from Benzinga Newsdesk
Pliant Therapeutics, Inc. (NASDAQ:PLRX) announced positive data from a Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis and suspected moderate to severe liver fibrosis. The trial met its primary and secondary endpoints, showing that bexotegrast was well tolerated and its plasma concentrations increased with dose. The drug also showed statistically significant differences in reducing liver fibrosis markers at the 160 mg dose relative to placebo at Week 12. Interim data from the high-dose 320 mg cohort is expected in Q1 2024.
September 26, 2023 | 11:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pliant Therapeutics' successful Phase 2a trial of bexotegrast could positively impact the company's stock in the short term. The drug showed promising results in treating liver fibrosis, meeting primary and secondary endpoints. Further data from a high-dose cohort is expected in Q1 2024.
The successful trial results for bexotegrast, a drug developed by Pliant Therapeutics, could lead to increased investor confidence and a potential rise in the company's stock price. The announcement of further data in Q1 2024 could also maintain investor interest and support the stock's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100